Tiratricol

Phase 3

TherapeuticsMD, Inc. (TXMD)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Monocarboxylate Transporter 8 Deficiency

View Full Landscape

Drug Information

Target Indication

Monocarboxylate Transporter 8 Deficiency

Clinical Trial

NCT05579327

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/12/2025

Emcitate

Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

KarXTPhase 3

Psychosis Associated With Alzheimer's Disease

DexycuPhase 3

Inflammation

enclomiphene citratePhase 3

Effect of Treatment on Bone Mineral Density

REL-1017Phase 3

Major Depressive Disorder

ETC-1002Phase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts